Asset Details
Do you wish to reserve the book?
Pharmacological Approaches to Inhibit Endogenous Glucose Production as a Means of Anti-diabetic Therapy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Pharmacological Approaches to Inhibit Endogenous Glucose Production as a Means of Anti-diabetic Therapy
Do you wish to request the book?
Pharmacological Approaches to Inhibit Endogenous Glucose Production as a Means of Anti-diabetic Therapy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Pharmacological Approaches to Inhibit Endogenous Glucose Production as a Means of Anti-diabetic Therapy
2001
Overview
The inappropriate overproduction of glucose by the liver is one of the key contributors to the hyperglycaemia of the diabetic state, and thus is a logical site of intervention for novel anti-diabetic approaches. Metformin is the only currently marketed anti-hyperglycaemic drug whose action is attributed largely to its having inhibitory effects on hepatic glucose production, but its molecular site and mechanism(s) of action remain unknown, whereas the liver acting PPARalpha agonists have their effects primarily on lipid metabolism. This review therefore rather focuses on candidate molecular targets within the liver for anti-hyperglycaemic therapy, and describes potential rate-controlling receptors and enzymes within the glucose producing pathways (glycogenolysis and gluconeogenesis). Most focus is directed towards inhibitors of the enzymes glucose-6-phosphatase, fructose-1,6-bisphosphatase and glycogen phosphorylase, and towards glucagon receptor antagonists, as these appear to be the most advanced in preclinical and clinical development, although progress with other potential targets is also described. Evidence of the anti-diabetic potential of such agents from animal studies is presented, and the relative merits of each approach are reviewed and compared. It is likely that such agents will become important additions to the therapeutic approaches to combat diabetes.
Publisher
Bentham Science Publishers Ltd,Bentham Science
Subject
/ Biological and medical sciences
/ Diabetes Mellitus, Type 2 - drug therapy
/ Diabetes Mellitus, Type 2 - metabolism
/ General and cellular metabolism. Vitamins
/ Glucose - antagonists & inhibitors
/ Humans
/ Hypoglycemic Agents - chemistry
/ Hypoglycemic Agents - pharmacology
